Soon-Shiong immuno-oncology startup NantCell rakes in $57M
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Two of Patrick Soon-Shiong’s NantWorks startups net $250M
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Soon-Shiong outfit NantCell raises $75M; focus is on cancer immunotherapy
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.